![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Wednesday, January 06, 2016 9:12:41 PM
I don't know if people recognize this, but the DCVax-Direct program was talked about for about a decade or so before the phase I clinical trial began -- even though the company knew how great its potential was.
My thinking is that Dr. Bosch took Dr. Triozzi's words from a decade and a half ago to heart:
IT DC therapy has potential advantages over alternate approaches. It avoids the necessity of identifying a specific tumor-associated antigen while increasing the spectrum of relevant antigens available for presentation. IT DC therapy may be applied practically in a variety of clinical situations, including patients with small tumors. Several issues will need to be addressed before this approach becomes clinically useful. Although an immune response to HSP-associated tumor antigens may be operational, the mechanism of the tumor regressions observed and the mechanism of failure will require further study. It is possible that DCs in other states of differentiation may be more effective after IT injection. More importantly, whether or not the antitumor immunologic activity observed in situ can be expanded systemically will need to be established. -- Dr. Triozzi
I'd highlight some words or phrases above, but I think the entire passage (every thought) stands on its own. It is, in my estimation, extremely prescient, and I believe Dr. Bosch and colleagues devoted a number of preclinical years to fulfill Dr. Triozzi's premise and heed his advice.
LP had to "buy" science time, and there is no question some can attempt to paint her as a charlatan. Instead, I'd suggest she is a critical member of the team engaged in developing a new field.
This ain't no fast food, but then, I've always appreciated slow cooking.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM